🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Researchers at MICHR developed the Clinical Trial Protocol Quality Rating Tool (PQRT) to evaluate protocol document quality. This tool offers a simple, reliable method to assess and to improve protocol quality. Read more here: #CTS #ASCPTjournalfamily ascpt.onlinelibrary.wiley.com/doi/10.1111/ct…

Cannabidiol boosts tacrolimus exposure: So et al. report a 4-fold ↑ in Cmax and 3-fold ↑ in AUC in healthy volunteers, highlighting a DDI with implications for transplant patients. Learn more: bit.ly/3EXr1Sg ASCPT Alexandria #CPTJournal

🧪 Paper of the Month – May 2025 A new translational #PKPD model predicts CAR expression after in vivo mRNA-loaded NP delivery of CAR-Ts. 🔍 Focus on intracellular mRNA stability 📊 Supports dose optimization & translation to humans Read here🔗 bit.ly/3YMjxrR

At #ASCPT2025, engage with fellow authors at our journal session, Journal Family: Meet the Author, held on Thursday, May 29, from 3:30–4:30 PM. The session will highlight authors from three recent themed issues! Register here: bit.ly/41Nx2Iw

🎓 Meet Veronica Olaker (Vern Olaker, MPH), 3rd-year med student CWRU School of Medicine & MPH grad! Her research spans #EHR data, clinical informatics & big data. She’s applying to #urology residency this year. 🎥 Watch her #StudentHighlight interview here!

Shape the future of #ClinicalPharmacology and #TranslationalScience and make your mark - submit a session proposal for #ASCPT2026! bit.ly/2JHcTu7

Listen as #CTS Associate Editor Sonal Singh and Guest Editor Zachary Taylor discuss the open #Biomarkers Call for Papers and what themes they’d like to see covered in this upcoming special collection. #ASCPTjournalfamily #podcast #CTS #biosimilars lnkd.in/e85npEBc

What’s holding back model-informed precision dosing? Dibbets et al. review key barriers (e.g. data gaps, unclear regs) and enablers (usability, collaboration) to help bring MIPD to the bedside. Learn more: bit.ly/3ZhwaLI ASCPT Alexandria #CPTJournal

"Everything You Wanted to Know About the ASCPT Leadership Accelerator" starts in just one hour (2 pm ET). Learn about this exciting program from the first participants in it! bit.ly/3FaZhtk

Learn about these cutting edge tools and more at next week's #ASCPT2025 Post-conference: "PK/PD modeling, QSP, PBPK & AI/ML for drug development". bit.ly/3YgKPGN

New in our Mechanism of Action series! Teclistamab is the 1st approved BCMA × CD3 bispecific antibody for patients with multiple myeloma. A new @CTS_journal review explores its MoA, PK/PD, & clinical development. 📖 Read: doi.org/10.1111/cts.13… 🎞️ Watch the video here 👇

With State of the Art and Featured Speakers like Michelle Werner of @Alltrna, Colin Pillai, and Brian Corrigan, #ASCPT2025 is jam packed with exciting scientific content! bit.ly/3Hb77nq

A comprehensive safety exposure-response analysis supported the selection of the ritlecitinib 50 mg non-loading dose regimen for alopecia areata patients including both adults and adolescents. Read the insights from Huh et al: bit.ly/437XQDW #PSPjournal #ASCPTjournals

Join us in person for the #ASCPT2025 Post-conference on May 31 to learn how quantitative approaches can transform your work in bringing medicines to patients faster and more effectively. bit.ly/3YgKPGN

The Annual Meeting is almost here! It's not too late to register and join us at National Harbor! #ASCPT2025 bit.ly/2EVZdcx *Pre-registration is required to participate on Wednesday, May28.

💊 Predicting PK before synthesis? ML says yes. New blog compares 4 ML approaches to model IV PK from chemical structure alone. Results? ML > traditional NCA. 🚀 A step forward in faster, smarter drug discovery. 📖 Read the Translational Byte: bit.ly/3F54Jy9

A popPK/PD + machine learning analysis highlights how the therapeutic responsiveness to paroxetine can be anticipated from its cumulative exposure, underscoring the clinical relevance of assessing SSRI blood concentrations: bit.ly/3H9Dd2U #PSPjournal #ASCPTjournals

How likely are cell & gene therapies to reach approval? Elsallab et al. map 30 years of CGT development, showing just a 5% success rate overall—higher with orphan status, lower in oncology. bit.ly/4mq6gj5 ASCPT Alexandria #CPTJournal

New study using QST modeling with DILIsym shows similar PK and liver injury risk for APAP-IR and APAP-ER overdoses—even in chronic alcohol users or those with low hepatic glutathione: bit.ly/4jiurwR #PSPjournal #ASCPTjournals #ClinicalPharmacology

New analysis using QTcTBT, a novel HR-corrected method, confirms QT prolongation effect of bedaquiline metabolite M2 (~7 ms) in MDR-TB patients—aligning with QTcF-based models but offering improved accuracy for tachycardic populations: bit.ly/4jcpVA4 #PSPjournal